Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | Cristina Saura, Mafalda Oliveira, Yin-Hsun Feng, Ming-Shen Dai, Sara A. Hurvitz, Sung-Bae Kim, Beverly Moy, Suzette Delaloge, William John Gradishar, Norikazu Masuda, Marketa Palacova, Maureen E. Trudeau, Johanna Mattson, Yoon Sim Yap, Richard Bryce, Bin Yao, Judith D. Bebchuk, Kiana Keyvanjah, Adam Brufsky | ||||||||||||
Title | Neratinib + capecitabine versus lapatinib + capecitabine in patients with HER2+ metastatic breast cancer previously treated with >= 2 HER2-directed regimens: Findings from the multinational, randomized, phase III NALA trial. | ||||||||||||
|
|||||||||||||
URL | https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.1002 | ||||||||||||
Abstract Text | J Clin Oncol 37, no. 15_suppl (May 20, 2019) 1002-1002 |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|